{"gene":"FOXA1","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":2010,"finding":"FOXA1 acts as a pioneer factor that determines genome-wide ER chromatin binding and gene expression; almost all ER-chromatin interactions depended on FOXA1 presence, and FOXA1 influenced genome-wide chromatin accessibility. CTCF was identified as an upstream negative regulator of FOXA1-chromatin interactions.","method":"ChIP-seq, siRNA knockdown, chromatin accessibility assays in breast cancer cells","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq with loss-of-function showing near-complete dependency of ER binding on FOXA1; highly cited, replicated finding","pmids":["21151129"],"is_preprint":false},{"year":2019,"finding":"Class-1 FOXA1 wing-2 domain mutations enhance chromatin mobility and binding frequency, strongly transactivating a luminal androgen-receptor program. Class-2 C-terminal truncation mutations increase DNA affinity enabling dominant chromatin binding and promote WNT pathway-driven metastasis through TLE3 inactivation. Class-3 rearrangements reposition a regulatory element (FOXMIND) to drive FOXA1 overexpression.","method":"Aggregate cohort genomic analysis, functional cell-based assays, structural classification of mutations","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — large cohort (1,546 cancers) with functional mechanistic follow-up across three structurally distinct mutation classes","pmids":["31243372"],"is_preprint":false},{"year":2019,"finding":"Wing-2 FOXA1 mutations confer gain-of-function with exaggerated pro-luminal differentiation; R219 mutations block luminal differentiation and activate a neuroendocrine/mesenchymal program by altering DNA-binding preference from canonical (GTAAAC/T) to a non-canonical motif (GTAAAG/A), as shown by ATAC-seq and reporter assays.","method":"Mouse prostate organoid proliferation assays, ATAC-seq, reporter assays, mutagenesis of 14 FOXA1 variants","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (ATAC-seq, organoid assays, reporter with motif mutagenesis) in one rigorous study","pmids":["31243370"],"is_preprint":false},{"year":2020,"finding":"LSD1 (KDM1A) associates with FOXA1 and promotes FOXA1 chromatin binding by demethylating FOXA1 at lysine-270, adjacent to the wing-2 region of the forkhead DNA-binding domain. LSD1 inhibition globally disrupts FOXA1 chromatin binding and downstream androgen-receptor binding.","method":"Co-IP, ChIP-seq, in vitro demethylation assays, site-directed mutagenesis of K270, in vivo xenograft models","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical demethylation assay with mutagenesis plus genome-wide ChIP-seq and in vivo validation","pmids":["32868907"],"is_preprint":false},{"year":2021,"finding":"EZH2 methylates FOXA1 at lysine-295; this methylation is recognized by BUB3, which recruits USP7 deubiquitinase to remove ubiquitination and stabilize FOXA1 protein. This PTM cascade promotes prostate cancer growth and cell cycle gene regulation.","method":"In vitro methylation assays, Co-IP, ubiquitination assays, siRNA knockdown, xenograft tumor models","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro methylation assay plus Co-IP/ubiquitination assays identifying writer (EZH2), reader (BUB3), and eraser (USP7) in single study","pmids":["33827814"],"is_preprint":false},{"year":2023,"finding":"SETD7 is the methyltransferase responsible for methylating FOXA1 at K270, counteracting LSD1-mediated demethylation; SETD7-mediated K270 methylation disrupts FOXA1 chromatin binding and transcriptional activity, and SETD7 acts as a tumor suppressor in prostate cancer.","method":"In vitro methyltransferase assay, ChIP-seq, knockdown/overexpression experiments, prostate cancer cell and in vivo models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro methyltransferase assay identifying specific writer enzyme plus genome-wide functional validation","pmids":["37549269"],"is_preprint":false},{"year":2016,"finding":"FOXA1 associates with DNA repair complexes and is required for genomic targeting of DNA polymerase β (POLB). FOXA1-mediated recruitment of POLB drives lineage-specific DNA demethylation at FOXA1-bound regions, and this demethylation is tightly coupled to ER genomic targeting and estrogen responsiveness.","method":"Co-IP, genome-wide DNA methylome, POLB ChIP-seq, FOXA1 depletion with rescue, overexpression studies","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with genome-wide methylome and ChIP-seq, multiple orthogonal approaches in one study","pmids":["27500525"],"is_preprint":false},{"year":2016,"finding":"FOXA1 induces TET1 expression by direct binding to TET1 cis-regulatory elements and physically interacts with TET1 protein through its CXXC domain, forming a feed-forward loop that maintains DNA hypomethylation and H3K4 methylation at lineage-specific enhancers to potentiate FOXA1 chromatin recruitment.","method":"ChIP-seq, Co-IP, TET1 depletion, genome-wide methylation analysis, reporter assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus genome-wide ChIP-seq and methylation data, multiple orthogonal methods","pmids":["27257062"],"is_preprint":false},{"year":2014,"finding":"FOXA1 is not required for AR direct chromatin binding at high-affinity AREs, but recruits AR to low-affinity half-AREs by opening chromatin around adjacent FKHD sites. Excess FOXA1 creates chromatin reservoirs retaining AR via half-AREs; FOXA1 downregulation releases AR to broadly bind AREs genome-wide even without androgen, revealing a dual pioneer and AR-inhibitory role.","method":"ChIP-seq, siRNA knockdown/overexpression, FOXA1 titration experiments in prostate cancer cells","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq with mechanistic titration experiments showing cooperativity and equilibrium","pmids":["24875621"],"is_preprint":false},{"year":2012,"finding":"FoxA1 depletion causes significant redistribution of both androgen receptor (AR) and glucocorticoid receptor (GR) cistromes in a cell-type- and receptor-specific manner, demonstrating a function for FoxA1 beyond pioneer activity in specifying cell-type specificity of steroid receptor binding.","method":"ChIP-seq after FOXA1 depletion, gene expression profiling in LNCaP-1F5 and VCaP cells","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-seq with loss-of-function across two cell lines and two receptors","pmids":["23269278"],"is_preprint":false},{"year":2010,"finding":"FOXA1 is essential for ERα expression in mammary gland; Foxa1-null mice show loss of ERα expression and failure of hormone-induced ductal morphogenesis with absent terminal end buds, while GATA3 expression is maintained. In breast cancer cell lines, FOXA1 directly regulates ERα expression.","method":"Foxa1 knockout mouse model, mammary gland phenotyping, breast cancer cell line knockdown, RT-PCR and immunostaining","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout mouse with defined phenotype, replicated in cell lines","pmids":["20501593"],"is_preprint":false},{"year":2005,"finding":"Foxa1 and Foxa2 together are required for lung branching morphogenesis; double-knockout inhibits cell proliferation, epithelial differentiation, and branching with loss of Shh signaling. Foxa1 and Foxa2 regulate Shh and Shh-dependent genes in respiratory epithelial cells.","method":"Conditional double-knockout mouse models (Foxa2Δ/Δ;Foxa1-/-), gene expression analysis, histology","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic double-knockout with defined pathway (Shh) and phenotypic rescue analysis","pmids":["15668254"],"is_preprint":false},{"year":2021,"finding":"In NEPC, FOXA1 is reprogrammed from androgen-receptor-associated to neuroendocrine-specific regulatory elements. NEPC requires FOXA1 for proliferation and NE lineage gene expression. Ectopic expression of ASCL1 and NKX2-1 in prostate adenocarcinoma cells is sufficient to reprogram FOXA1 binding to NE regulatory elements and induce enhancer activity.","method":"ChIP-seq (histone modifications), FOXA1 knockdown, ectopic TF expression, patient-derived xenografts","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq in PDX models plus functional knockdown and ectopic TF reprogramming with multiple orthogonal methods","pmids":["33785741"],"is_preprint":false},{"year":2018,"finding":"FOXA1 directly occupies an upstream enhancer of TGFB3 to inhibit its transcription; FOXA1 loss upregulates TGFβ3, which activates TGF-β signaling, EMT, and cell motility. Pharmacological TGF-β receptor I inhibition blocks FOXA1 loss-induced invasion.","method":"ChIP assay, siRNA knockdown, SMAD2 phosphorylation measurement, tissue microarray, xenograft invasion assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP confirming direct enhancer occupancy plus in vivo xenograft rescue with pharmacological inhibitor","pmids":["30511964"],"is_preprint":false},{"year":2017,"finding":"FOXA1 directly binds the promoter of IL-8 to inhibit its expression; FOXA1 loss induces IL-8, which activates MAPK/ERK pathway (ERK phosphorylation) and ENO2 expression, driving neuroendocrine differentiation. IL-8 knockdown or ERK inhibition abolishes FOXA1 loss-induced NE differentiation.","method":"ChIP assay, siRNA knockdown, ERK phosphorylation assay, IL-8 blockade, xenograft models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP establishing direct promoter binding plus pathway validation by multiple perturbations","pmids":["28319070"],"is_preprint":false},{"year":2022,"finding":"FOXA1 directly binds an intragenic enhancer of HIF1A to inhibit its expression; FOXA1 downregulation induces hypoxia transcriptional programs via HIF1A, which upregulates CCL2 to promote immunosuppressive macrophage infiltration and cancer cell invasion.","method":"ChIP assay, siRNA knockdown, HIF1A pharmacological inhibition, macrophage infiltration assays, xenograft invasion studies","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct enhancer binding plus functional cascade validation with pharmacological inhibitors","pmids":["35931888"],"is_preprint":false},{"year":2021,"finding":"FOXA1 binds the STAT2 DNA-binding domain and suppresses STAT2 DNA-binding activity and IFN signaling gene expression, suppressing cancer immune response independently of FOXA1 transactivation activity and independently of FOXA1 cancer mutations.","method":"Co-IP, ChIP, siRNA knockdown, IFN signaling gene expression assays in prostate and breast cancer cells and mouse models","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP establishing direct STAT2 interaction plus functional gene expression and in vivo validation","pmids":["34101624"],"is_preprint":false},{"year":2023,"finding":"FOXA1 forms submicron condensates through N- and C-terminal intrinsically disordered regions (IDRs); these IDRs enable FOXA1 to dissolve condensed chromatin. DNA-binding capacity contributes to both condensate formation and condensed-chromatin dissolution. IDR-mediated condensate formation governs FOXA1 binding to condensed chromatin to regulate proliferation and migration.","method":"Live-cell imaging, FRAP, condensate dissolution assays, genome-wide ATAC-seq, IDR deletion mutagenesis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution-like condensate assays with mutagenesis of IDRs and genome-wide functional validation","pmids":["38101414"],"is_preprint":false},{"year":2024,"finding":"Covalent small molecules react with FOXA1 at C258 within the forkhead DNA-binding domain in a DNA-dependent manner, redistributing FOXA1 genome-wide binding and altering chromatin accessibility. Motif analysis indicates ligands relax canonical DNA-binding preference by strengthening interactions with suboptimal sequences near C258.","method":"Chemical proteomics, ChIP-seq, ATAC-seq, covalent ligand competition assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — covalent site-specific modification with structural mechanism plus genome-wide ChIP-seq and ATAC-seq validation","pmids":["39413792"],"is_preprint":false},{"year":2005,"finding":"Both Foxa1 and Foxa2 physically interact with the DNA-binding domain of AR via GST pull-down; this interaction enables Foxa proteins to be recruited to AR binding sites without a Foxa binding site, and AR can be recruited to Foxa binding sites without an AR binding site. Foxa1 regulates prostate-specific genes (PSA, probasin) while Foxa2 regulates epididymis-specific genes (mE-RABP).","method":"GST pull-down, gel-shift (EMSA), ChIP, transient transfection reporter assays","journal":"Annals of the New York Academy of Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — GST pull-down plus EMSA and ChIP, single lab","pmids":["16467259"],"is_preprint":false},{"year":2006,"finding":"FOXA1 binds a specific site in the p27(Kip1) promoter (within the BRCA1-responsive element) to activate p27 transcription. BRCA1 co-expression synergistically activates the p27 promoter and increases FOXA1 protein half-life. Mutation of the FOXA1 binding site abrogates both FOXA1 and BRCA1-mediated activation.","method":"EMSA with supershift, transient transfection reporter assays, mutagenesis, half-life analysis, siRNA knockdown of BRCA1","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA with supershift confirming direct DNA binding plus mutagenesis of binding site, single lab","pmids":["16331276"],"is_preprint":false},{"year":2014,"finding":"FOXA1 SUMOylation occurs at K6, K389, and K267 (proximal to the DNA-binding domain). Mutation of SUMO sites slows FOXA1 nuclear mobility (FRAP) and further retards AR mobility, enhances FOXA1 chromatin occupancy at the PSA locus, increases FOXA1 transcriptional activity with AR, and alters LNCaP cell proliferation.","method":"SUMOylation assays in COS-1 cells, FRAP in HEK293 cells, ChIP, gene expression assays in LNCaP cells","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct SUMOylation assay with site mutagenesis plus FRAP and ChIP, single lab","pmids":["25127374"],"is_preprint":false},{"year":2018,"finding":"A compact palindromic DNA element (DIV) induces FOXA1 homodimerization with strongly positive cooperativity, strictly constrained by precise half-site spacing. FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted, and DIV sites show increased accessibility in response to PI3K inhibition.","method":"ChIP-seq reanalysis, EMSA cooperativity assays, reporter gene assays, structural modeling","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA demonstrating cooperativity with spacing mutagenesis plus reporter assays and ChIP-seq, single lab","pmids":["29669022"],"is_preprint":false},{"year":2020,"finding":"Wing-2 FOXA1 mutations in breast cancer display increased chromatin binding at ER loci upon estrogen stimulation and enhanced ER-mediated transcription without changes in chromatin accessibility. The breast cancer-specific SY242CS mutation opens distinct chromatin regions and activates an alternative cistrome through a conformational change enabling stable binding to a non-canonical DNA motif.","method":"ChIP-seq, ATAC-seq, structural modeling, breast cancer patient cohort analysis","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq and ATAC-seq distinguishing mechanistic effects of two mutation classes in breast cancer models","pmids":["32888433"],"is_preprint":false},{"year":2014,"finding":"FOXA1 directly inhibits EZH2 histone methyltransferase activity through its C-terminal histone-binding motif, opposing EZH2-mediated CDKN2A repression. Loss of FOXA1 is required, in addition to EZH2 overexpression, to bypass RAS-induced senescence via CDKN2A silencing.","method":"In vitro HMTase assay, epistasis experiments (siRNA double knockdown), oncogenic transformation assays in prostate and breast cancer cells","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro HMTase inhibition assay plus epistasis, single lab, limited mechanistic detail in abstract","pmids":["25264199"],"is_preprint":false},{"year":2009,"finding":"Foxa1 and Foxa2 are essential for differentiation of intestinal goblet cells (via Muc2 regulation) and enteroendocrine L- and D-cells (glucagon-like peptide, somatostatin, peptide YY); double intestinal-specific knockout reduces expression of Islet-1 and Pax6, placing Foxa1/2 upstream of a broader enteroendocrine transcription factor network.","method":"Villin-Cre conditional double-knockout mice, immunohistochemistry, RT-PCR, mRNA quantification","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean tissue-specific double-knockout with defined cellular phenotypes and gene expression targets","pmids":["19737569"],"is_preprint":false},{"year":2010,"finding":"Foxa1 and Foxa2 together control expression of ChREBP (Mlxipl) directly in beta cells; combined inactivation causes impaired glucose-stimulated insulin secretion and calcium oscillations more severe than Foxa2 alone, and elevates neural differentiation genes, demonstrating redundant and distinct roles in maintaining beta-cell metabolic and secretory identity.","method":"Inducible conditional double-knockout mice, glucose tolerance tests, calcium imaging, RNA expression profiling","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible KO with direct functional readouts (insulin secretion, calcium oscillations) and ChREBP target gene analysis","pmids":["20534694"],"is_preprint":false},{"year":2010,"finding":"Foxa2 directly binds Gli2 genomic regulatory regions (confirmed by ChIP) and, together with Foxa1, attenuates Shh signaling by inhibiting Gli2 transcription in ventral midbrain progenitors. Loss/gain-of-function studies show Foxa1 and Foxa2 positively regulate Shh expression while also negatively regulating its downstream transducer Gli2.","method":"ChIP, conditional Wnt1-Cre;Foxa2flox/flox knockout, gain-of-function in mice","journal":"Mechanisms of development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct Gli2 binding plus genetic loss/gain-of-function, single lab","pmids":["21093585"],"is_preprint":false},{"year":2021,"finding":"NEDD4 physically interacts with FOXA1 (Co-IP) and triggers its ubiquitination and proteasomal degradation. FOXA1 transcriptionally activates miR-340-5p, which binds ATF1 mRNA. NEDD4-mediated FOXA1 destabilization thus suppresses miR-340-5p and elevates ATF1 to promote colon cancer progression.","method":"Co-IP, ubiquitination assay, ChIP, luciferase reporter assay, siRNA experiments in colon cancer cells","journal":"RNA biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination assay identifying E3 ligase-substrate relationship, single lab","pmids":["33530829"],"is_preprint":false},{"year":2020,"finding":"ZFP91 ubiquitinates FOXA1 and promotes its degradation; ZFP91 knockdown reduces FOXA1 polyubiquitination, increases FOXA1 protein stability, and sensitizes gastric cancer cells to chemotherapy.","method":"Co-IP, ubiquitination assay, ZFP91 siRNA knockdown, protein stability measurement","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay identifying E3 ligase plus functional consequences, single lab","pmids":["31046116"],"is_preprint":false},{"year":2015,"finding":"Nuclear receptor SHP inhibits FOXA1-mediated transcriptional activation of Bhmt (betaine-homocysteine methyltransferase) and cystathionine γ-lyase, controlling oscillatory homocysteine metabolism in mice.","method":"ChIP, RNA-seq, metabolomics in SHP-null mice, dietary manipulation experiments","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP in vivo plus SHP-null mouse phenotype and metabolomics, single lab","pmids":["25701738"],"is_preprint":false},{"year":2014,"finding":"FOXA1 interacts with AR (Co-IP) in endometrial cancer cells and both bind directly to the MYC promoter and enhancer (ChIP). FOXA1 promotes AR-mediated transcription of XBP1, MYC, ZBTB16, and UHRF1, activating Notch1/Hes1 expression in an AR-dependent manner to promote cancer cell proliferation.","method":"Co-IP, ChIP-PCR, siRNA/shRNA knockdown, transfection reporter assays, xenograft tumor formation","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and ChIP-PCR establishing direct protein interaction and DNA binding, single lab","pmids":["24512546"],"is_preprint":false},{"year":2016,"finding":"Twist1 represses FOXA1 expression by binding the FOXA1 proximal promoter and recruiting the NuRD transcriptional repressor complex to de-acetylate H3K9 and inhibit RNA polymerase II recruitment, and by blocking AP-1 recruitment. Restored FOXA1 expression in Twist1-expressing cells reduces integrin α5, integrin β1 and MMP9 and inhibits invasion/metastasis.","method":"ChIP, promoter reporter assays, Co-IP (NuRD recruitment), siRNA/overexpression, xenograft metastasis models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct promoter binding and NuRD complex recruitment plus functional invasion assays, single lab","pmids":["27524420"],"is_preprint":false},{"year":2008,"finding":"PPARγ activation induces FOXA1 expression as an intermediary transcription factor; FOXA1 (and IRF-1) bind UPK1a, UPK2, and UPK3a promoters (confirmed by EMSA) and their siRNA knockdown abrogates PPARγ-induced uroplakin expression, placing FOXA1 downstream of PPARγ in a urothelial differentiation program.","method":"Microarray, EMSA, siRNA knockdown, gene expression analysis in primary normal human urothelial cells","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA confirming direct DNA binding plus siRNA epistasis showing pathway dependency, single lab","pmids":["18688264"],"is_preprint":false},{"year":2022,"finding":"FOXA1 directly binds regulatory regions of splicing-related genes including HNRNPK and SRSF1, controlling their expression and thereby orchestrating alternative splicing dysregulation across prostate cancer transcriptomes through an 'exon definition' mechanism that reduces NMD-targeted isoforms.","method":"ChIP-seq, transcriptome analysis of 500 prostate cancer samples, siRNA knockdown, functional cell proliferation assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq plus large-scale transcriptome analysis with functional validation, single lab","pmids":["36170835"],"is_preprint":false},{"year":2023,"finding":"O-GlcNAcylation of FOXA1 at Thr432, Ser441, and Ser443 regulates FOXA1 protein stability and chromatin assembly. O-GlcNAcylation triggers recruitment of the transcriptional repressor MeCP2 to FOXA1, switching FOXA1 chromatin-binding sites to adhesion-related gene loci (EPB41L3, COL9A2) to promote breast cancer metastasis.","method":"Site-specific mutagenesis, Co-IP, ChIP-seq, ATAC-seq, in vitro and in vivo metastasis assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-specific PTM mutagenesis with Co-IP identifying reader (MeCP2) plus genome-wide ChIP-seq and in vivo validation","pmids":["37595040"],"is_preprint":false},{"year":2022,"finding":"CREB5 physically interacts with FOXA1 and AR at transcription regulatory elements active in mCRPC, reprogramming FOXA1 nuclear protein-protein interaction network in response to enzalutamide. CREB5/FOXA1 co-interacting factors TBX3 and NFIC regulate cell viability and ART resistance.","method":"ChIP-seq, rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME), Co-IP, patient transcriptome analysis","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIME/Co-IP identifying nuclear interaction partners with ChIP-seq validation, single lab","pmids":["35550030"],"is_preprint":false},{"year":2024,"finding":"NSD2 associates with FOXA1 at tumor-specific AR enhancers containing the chimeric FOXA1:AR half-motif; NSD2 inactivation disrupts >65% of the AR cistrome and impairs AR transactivation. NSD2 H3K36 dimethyltransferase activity is required for these AR/FOXA1-dependent enhancer circuitries.","method":"ChIP-seq, NSD2 inactivation, FOXA1 ChIP, motif analysis, PROTAC degrader studies in prostate cancer models","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq with genetic inactivation and pharmacological degradation, identifying NSD2 as essential co-factor at FOXA1:AR enhancers","pmids":["39251788"],"is_preprint":false},{"year":2024,"finding":"FOXA1-mediated repression of GR (NR3C1) occurs via the corepressor TLE3; FOXA1 silencing potentiates GR chromatin binding and transcriptional activity rather than restricting it. Pre-accessible chromatin sites with FOXA1 occupancy are the exclusive sites of AR-to-GR replacement under enzalutamide treatment.","method":"Genome-wide ChIP-seq, ATAC-seq, FOXA1 siRNA silencing, TLE3 Co-IP/ChIP in prostate cancer cells","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-seq and ATAC-seq with FOXA1 silencing revealing mechanistic TLE3-corepressor link, single lab","pmids":["38015476"],"is_preprint":false},{"year":2017,"finding":"FOXA1 transcriptionally activates the PLOD2 promoter by directly binding it; this occurs downstream of a PI3K/AKT signaling axis (EGFR-PI3K/AKT-FOXA1-PLOD2), and elevated PLOD2 promotes NSCLC metastasis by enhancing migration and collagen reorganization.","method":"ChIP assay, luciferase reporter assay, siRNA knockdown, orthotopic implantation metastasis model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay confirming direct promoter binding, with in vivo metastasis validation, single lab","pmids":["29072684"],"is_preprint":false},{"year":2015,"finding":"FOXA1 depletion in CRPC cells abrogates oncogenic potential of constitutively active AR variants (AR-Vs); ~41% of the AR-V transcriptome requires FOXA1, and FOXA1 depletion attenuates AR-V chromatin binding at co-regulated genes. AR-V protein levels paradoxically increase upon FOXA1 loss due to loss of negative feedback on the AR gene.","method":"FOXA1 siRNA/shRNA knockdown, gene expression profiling, AR-V ChIP, proliferation assays in CWR22Rv1 cells","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus genome-wide expression profiling with loss-of-function, single lab","pmids":["26336819"],"is_preprint":false},{"year":2014,"finding":"Foxa1 and Foxa2 directly bind and activate promoter regions of Nkx2.2, Kir6.2, Sur1, Gipr, Isl1, and Pou3f4 genes in alpha cells. Foxa1 specifically regulates glucagon gene expression through the G2 element, while combined Foxa1/Foxa2 depletion is required to affect glucagon secretion.","method":"siRNA knockdown of Foxa1 and Foxa2 in primary rat alpha cells, ChIP, qPCR, glucagon secretion assays","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP in primary cells confirming direct promoter binding plus functional secretion assays, single lab","pmids":["25057789"],"is_preprint":false},{"year":2017,"finding":"Pioneer factors FOXA1 and FOXA2 are required for glucocorticoid receptor (GR) recruitment to the LEFTY1 promoter in endometrial cells; E2 antagonizes glucocorticoid-mediated LEFTY1 induction by reducing FOXA1, FOXA2, and GR recruitment. Multiple additional GR-dependent genes require FOXA1/2 for induction.","method":"ChIP showing GR and FOXA1/2 co-recruitment, siRNA knockdown of FOXA1/2, gene expression profiling in immortalized and primary human endometrial cells","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating co-recruitment with functional knockdown, single lab","pmids":["28938408"],"is_preprint":false},{"year":2023,"finding":"FOXA1 directly binds the MND1 promoter to inhibit its transcription (ChIP and luciferase assay); MND1 interacts with TKT (Co-IP and mass spectrometry) and activates the PI3K/AKT signaling axis to promote gastric cancer progression and oxaliplatin resistance.","method":"Luciferase reporter assay, ChIP, Co-IP, mass spectrometry, siRNA knockdown, in vitro and in vivo assays","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus Co-IP/MS identifying downstream partner, single lab","pmids":["37817120"],"is_preprint":false}],"current_model":"FOXA1 is a pioneer transcription factor that binds condensed chromatin through its forkhead DNA-binding domain—aided by intrinsically disordered regions that form condensates to dissolve compact chromatin—and opens local chromatin to license binding of steroid hormone receptors (ERα, AR, GR); its chromatin occupancy and activity are post-translationally regulated by LSD1-mediated demethylation at K270 (stabilizing binding), SETD7-mediated methylation at K270 (disrupting binding), EZH2-mediated methylation at K295 recognized by BUB3/USP7 (stabilizing protein), SUMOylation at K6/K389/K267 (modulating nuclear mobility), O-GlcNAcylation at Thr432/Ser441/Ser443 (altering interactome and cistrome), and ubiquitination by NEDD4/ZFP91 (promoting degradation); FOXA1 also directly represses target gene transcription (TGFB3, IL-8, HIF1A, MND1) and suppresses IFN signaling by binding the STAT2 DNA-binding domain, while associating with DNA repair complexes to drive POLB-dependent DNA demethylation and cooperating with TET1 via a feed-forward loop to maintain lineage-specific enhancer hypomethylation."},"narrative":{"mechanistic_narrative":"FOXA1 is a pioneer transcription factor that opens compacted chromatin to license recruitment of steroid hormone receptors and to specify lineage-specific gene-expression programs across mammary, prostate, lung, intestinal, pancreatic, and urothelial tissues [PMID:21151129, PMID:15668254, PMID:19737569, PMID:20534694]. It establishes the genome-wide chromatin-binding landscape of estrogen receptor (almost all ERα–chromatin interactions depend on FOXA1) and reciprocally controls androgen-receptor and glucocorticoid-receptor cistromes in a cell-type- and receptor-specific manner; FOXA1 and AR can physically interact through the AR DNA-binding domain, enabling mutual recruitment to sites lacking a cognate motif [PMID:21151129, PMID:23269278, PMID:16467259]. Its pioneering capacity rests on a forkhead DNA-binding domain together with N- and C-terminal intrinsically disordered regions that drive condensate formation and dissolution of condensed chromatin [PMID:38101414]. Beyond licensing receptors, FOXA1 displays a dual inhibitory role—buffering AR and GR through chromatin reservoirs and the corepressor TLE3—so that FOXA1 loss can release receptors to bind chromatin more broadly [PMID:24875621, PMID:38015476]. FOXA1 also directly represses transcription of genes including TGFB3, IL-8, HIF1A, and MND1, restraining EMT, neuroendocrine differentiation, hypoxia programs, and invasion when present, and it suppresses interferon signaling by binding and inhibiting the STAT2 DNA-binding domain independently of its own transactivation [PMID:30511964, PMID:28319070, PMID:35931888, PMID:34101624]. FOXA1 chromatin occupancy and stability are tuned by an extensive post-translational code: LSD1 demethylates K270 to stabilize binding while SETD7 methylates the same residue to disrupt it, EZH2-mediated K295 methylation is read by BUB3 to recruit USP7 and stabilize the protein, SUMOylation and O-GlcNAcylation reshape mobility and cistrome, and the E3 ligases NEDD4 and ZFP91 target it for degradation [PMID:32868907, PMID:37549269, PMID:33827814, PMID:25127374, PMID:37595040, PMID:33530829, PMID:31046116]. FOXA1 further couples transcription to epigenome remodeling by recruiting DNA polymerase β to drive lineage-specific DNA demethylation and by forming a feed-forward loop with TET1 to maintain enhancer hypomethylation [PMID:27500525, PMID:27257062]. Cancer-associated mutations partition into mechanistically distinct classes that enhance chromatin mobility, increase DNA affinity, or relax DNA-motif preference to activate alternative cistromes and drive luminal, neuroendocrine, metastatic, or WNT-driven programs [PMID:31243372, PMID:31243370, PMID:32888433].","teleology":[{"year":2005,"claim":"Established that FOXA1 acts in tissue morphogenesis and engages steroid receptors directly, framing it as both a developmental regulator and a receptor partner.","evidence":"Foxa1/Foxa2 double-knockout mice for lung branching plus GST pull-down with the AR DNA-binding domain","pmids":["15668254","16467259"],"confidence":"High","gaps":["Mechanism of chromatin opening not yet addressed","AR interaction shown only by pull-down/EMSA in a single lab"]},{"year":2010,"claim":"Defined FOXA1 as the pioneer factor that dictates genome-wide ER binding and is essential for ERα expression and hormone-driven mammary morphogenesis, anchoring its role in hormone-responsive epithelia.","evidence":"ChIP-seq with siRNA knockdown in breast cancer cells and Foxa1-null mouse mammary phenotyping","pmids":["21151129","20501593"],"confidence":"High","gaps":["Biophysical basis of chromatin opening unresolved","Did not address regulation of FOXA1 itself"]},{"year":2014,"claim":"Revealed FOXA1 as a quantitative, dual regulator of AR—opening chromatin to recruit AR to low-affinity sites while also sequestering AR in reservoirs—rather than a simple positive pioneer.","evidence":"ChIP-seq with FOXA1 titration, knockdown, and overexpression in prostate cancer cells","pmids":["24875621"],"confidence":"High","gaps":["Did not define the corepressor mediating sequestration","Equilibrium parameters not measured biochemically"]},{"year":2016,"claim":"Connected FOXA1 transcriptional pioneering to active DNA-demethylation, showing it shapes the lineage epigenome through POLB recruitment and a TET1 feed-forward loop.","evidence":"Reciprocal Co-IP, genome-wide methylome, POLB ChIP-seq, and TET1 depletion experiments","pmids":["27500525","27257062"],"confidence":"High","gaps":["Direct enzymatic coupling of FOXA1 to demethylation machinery not reconstituted","Generality across non-breast lineages untested"]},{"year":2019,"claim":"Resolved the functional consequences of cancer mutations into structurally distinct classes that alter chromatin mobility, DNA affinity, or motif preference, explaining how FOXA1 alterations drive divergent oncogenic programs.","evidence":"Large cohort genomics with functional cell assays, organoid proliferation, ATAC-seq, and motif mutagenesis","pmids":["31243372","31243370"],"confidence":"High","gaps":["Structural details of altered DNA-binding inferred, not crystallographically resolved","In vivo tumor initiation by each class incompletely tested"]},{"year":2020,"claim":"Identified K270 methylation status as a switch controlling FOXA1 chromatin binding, with LSD1 demethylation stabilizing occupancy.","evidence":"Co-IP, in vitro demethylation assays, K270 mutagenesis, ChIP-seq, and xenografts","pmids":["32868907"],"confidence":"High","gaps":["Opposing writer not yet identified at this stage","Stoichiometry of modification in vivo unknown"]},{"year":2021,"claim":"Expanded the PTM code by defining EZH2→BUB3→USP7 K295 methyl-stabilization and a STAT2-binding immune-suppressive activity, plus NEDD4 ubiquitination, distinguishing FOXA1 stability and non-genomic functions.","evidence":"In vitro methylation/ubiquitination assays, Co-IP for STAT2 and NEDD4, ChIP, and in vivo models","pmids":["33827814","34101624","33530829"],"confidence":"High","gaps":["Interplay between competing PTMs not integrated","STAT2 suppression structural interface not mapped"]},{"year":2023,"claim":"Defined SETD7 as the K270 methyltransferase opposing LSD1 and established O-GlcNAcylation as a cistrome-switching modification recruiting MeCP2, completing a writer/eraser logic for FOXA1 regulation.","evidence":"In vitro methyltransferase assays, site-specific PTM mutagenesis, Co-IP, ChIP-seq, ATAC-seq, and metastasis models","pmids":["37549269","37595040"],"confidence":"High","gaps":["Combinatorial effect of K270 methylation and O-GlcNAcylation untested","Upstream signals controlling these enzymes in vivo unclear"]},{"year":2023,"claim":"Provided a biophysical basis for pioneering by showing FOXA1 IDRs form condensates that dissolve condensed chromatin.","evidence":"Live-cell imaging, FRAP, condensate dissolution assays, ATAC-seq, and IDR deletion mutagenesis","pmids":["38101414"],"confidence":"High","gaps":["Composition of FOXA1 condensates in vivo not defined","Link between condensates and specific PTMs unexplored"]},{"year":2024,"claim":"Demonstrated druggability and cofactor dependence of the FOXA1 cistrome through covalent C258 ligands that relax DNA preference and NSD2-dependent H3K36 methylation that sustains FOXA1:AR enhancers.","evidence":"Chemical proteomics, ChIP-seq, ATAC-seq, NSD2 genetic inactivation, and PROTAC degraders in prostate cancer models","pmids":["39413792","39251788"],"confidence":"High","gaps":["Therapeutic window of covalent ligands not established","How NSD2 is recruited specifically to FOXA1:AR sites unresolved"]},{"year":null,"claim":"How the full set of competing PTMs, condensate dynamics, and cofactor circuits are integrated to determine FOXA1's tissue- and context-specific cistrome remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified quantitative model linking PTM state to chromatin output","Structural mechanism of mutant motif relaxation not solved","In vivo interplay of activator vs repressor roles per tissue undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,13,14,16]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,18,22,23]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,16,38]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[17,21]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[0,17]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,13,14]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,8,9]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[10,11,25,26]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[6,7,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,2,23]}],"complexes":[],"partners":["AR","ESR1","LSD1","EZH2","TET1","STAT2","TLE3","NSD2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P55317","full_name":"Hepatocyte nuclear factor 3-alpha","aliases":["Forkhead box protein A1","Transcription factor 3A","TCF-3A"],"length_aa":472,"mass_kda":49.1,"function":"Transcription factor that is involved in embryonic development, establishment of tissue-specific gene expression and regulation of gene expression in differentiated tissues. Is thought to act as a 'pioneer' factor opening the compacted chromatin for other proteins through interactions with nucleosomal core histones and thereby replacing linker histones at target enhancer and/or promoter sites. Binds DNA with the consensus sequence 5'-[AC]A[AT]T[AG]TT[GT][AG][CT]T[CT]-3' (By similarity). Proposed to play a role in translating the epigenetic signatures into cell type-specific enhancer-driven transcriptional programs. Its differential recruitment to chromatin is dependent on distribution of histone H3 methylated at 'Lys-5' (H3K4me2) in estrogen-regulated genes. Involved in the development of multiple endoderm-derived organ systems such as liver, pancreas, lung and prostate; FOXA1 and FOXA2 seem to have at least in part redundant roles (By similarity). Modulates the transcriptional activity of nuclear hormone receptors. Is involved in ESR1-mediated transcription; required for ESR1 binding to the NKX2-1 promoter in breast cancer cells; binds to the RPRM promoter and is required for the estrogen-induced repression of RPRM. Involved in regulation of apoptosis by inhibiting the expression of BCL2. Involved in cell cycle regulation by activating expression of CDKN1B, alone or in conjunction with BRCA1. Originally described as a transcription activator for a number of liver genes such as AFP, albumin, tyrosine aminotransferase, PEPCK, etc. Interacts with the cis-acting regulatory regions of these genes. Involved in glucose homeostasis","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P55317/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FOXA1","classification":"Not Classified","n_dependent_lines":65,"n_total_lines":1208,"dependency_fraction":0.05380794701986755},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FOXA1","total_profiled":1310},"omim":[{"mim_id":"618656","title":"PROLINE- AND GLUTAMATE-RICH PROTEIN WITH COILED-COIL DOMAIN 1; PERCC1","url":"https://www.omim.org/entry/618656"},{"mim_id":"618053","title":"ANDROGEN RECEPTOR-REGULATED LONG NONCODING RNA 1; ARLNC1","url":"https://www.omim.org/entry/618053"},{"mim_id":"616387","title":"DOWNREGULATED RNA IN ANDROGEN-INDEPENDENT CELLS, NONCODING; DRAIC","url":"https://www.omim.org/entry/616387"},{"mim_id":"611539","title":"FORKHEAD BOX D3; FOXD3","url":"https://www.omim.org/entry/611539"},{"mim_id":"611416","title":"TOX HIGH MOBILITY GROUP BOX FAMILY MEMBER 3; TOX3","url":"https://www.omim.org/entry/611416"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli fibrillar center","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"prostate","ntpm":70.2}],"url":"https://www.proteinatlas.org/search/FOXA1"},"hgnc":{"alias_symbol":[],"prev_symbol":["HNF3A"]},"alphafold":{"accession":"P55317","domains":[{"cath_id":"1.10.10.10","chopping":"176-257","consensus_level":"high","plddt":91.673,"start":176,"end":257}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P55317","model_url":"https://alphafold.ebi.ac.uk/files/AF-P55317-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P55317-F1-predicted_aligned_error_v6.png","plddt_mean":55.66},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FOXA1","jax_strain_url":"https://www.jax.org/strain/search?query=FOXA1"},"sequence":{"accession":"P55317","fasta_url":"https://rest.uniprot.org/uniprotkb/P55317.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P55317/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P55317"}},"corpus_meta":[{"pmid":"21151129","id":"PMC_21151129","title":"FOXA1 is a key determinant of estrogen receptor function and endocrine response.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21151129","citation_count":699,"is_preprint":false},{"pmid":"31243372","id":"PMC_31243372","title":"Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/31243372","citation_count":243,"is_preprint":false},{"pmid":"31243370","id":"PMC_31243370","title":"FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/31243370","citation_count":224,"is_preprint":false},{"pmid":"15668254","id":"PMC_15668254","title":"Compensatory roles of Foxa1 and Foxa2 during lung morphogenesis.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15668254","citation_count":224,"is_preprint":false},{"pmid":"17671124","id":"PMC_17671124","title":"FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17671124","citation_count":207,"is_preprint":false},{"pmid":"20501593","id":"PMC_20501593","title":"FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.","date":"2010","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20501593","citation_count":202,"is_preprint":false},{"pmid":"23269278","id":"PMC_23269278","title":"FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23269278","citation_count":191,"is_preprint":false},{"pmid":"15567715","id":"PMC_15567715","title":"Immunohistochemical localization of Foxa1 and Foxa2 in mouse embryos and adult tissues.","date":"2004","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/15567715","citation_count":186,"is_preprint":false},{"pmid":"22115363","id":"PMC_22115363","title":"FOXA1: a transcription factor with parallel functions in development and cancer.","date":"2012","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/22115363","citation_count":178,"is_preprint":false},{"pmid":"24875621","id":"PMC_24875621","title":"Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24875621","citation_count":163,"is_preprint":false},{"pmid":"21934649","id":"PMC_21934649","title":"FOXA1: master of steroid receptor function in cancer.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21934649","citation_count":160,"is_preprint":false},{"pmid":"33785741","id":"PMC_33785741","title":"Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33785741","citation_count":134,"is_preprint":false},{"pmid":"32946061","id":"PMC_32946061","title":"Pioneer of prostate cancer: past, present and the future of FOXA1.","date":"2020","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/32946061","citation_count":132,"is_preprint":false},{"pmid":"19737569","id":"PMC_19737569","title":"Foxa1 and Foxa2 control the differentiation of goblet and enteroendocrine L- and D-cells in mice.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19737569","citation_count":131,"is_preprint":false},{"pmid":"27524420","id":"PMC_27524420","title":"Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27524420","citation_count":130,"is_preprint":false},{"pmid":"30511964","id":"PMC_30511964","title":"Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30511964","citation_count":127,"is_preprint":false},{"pmid":"28319070","id":"PMC_28319070","title":"FOXA1 inhibits prostate cancer neuroendocrine differentiation.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28319070","citation_count":122,"is_preprint":false},{"pmid":"15149721","id":"PMC_15149721","title":"About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer.","date":"2004","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15149721","citation_count":107,"is_preprint":false},{"pmid":"32868907","id":"PMC_32868907","title":"Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.","date":"2020","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32868907","citation_count":107,"is_preprint":false},{"pmid":"32888433","id":"PMC_32888433","title":"FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.","date":"2020","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/32888433","citation_count":100,"is_preprint":false},{"pmid":"20534694","id":"PMC_20534694","title":"Foxa1 and Foxa2 maintain the metabolic and secretory features of the mature beta-cell.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20534694","citation_count":98,"is_preprint":false},{"pmid":"29072684","id":"PMC_29072684","title":"PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29072684","citation_count":82,"is_preprint":false},{"pmid":"34101624","id":"PMC_34101624","title":"FOXA1 overexpression suppresses interferon signaling and immune response in cancer.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34101624","citation_count":80,"is_preprint":false},{"pmid":"16467259","id":"PMC_16467259","title":"Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially.","date":"2005","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16467259","citation_count":80,"is_preprint":false},{"pmid":"30475207","id":"PMC_30475207","title":"FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30475207","citation_count":66,"is_preprint":false},{"pmid":"16331276","id":"PMC_16331276","title":"BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1).","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16331276","citation_count":65,"is_preprint":false},{"pmid":"26527523","id":"PMC_26527523","title":"GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.","date":"2015","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26527523","citation_count":64,"is_preprint":false},{"pmid":"24512546","id":"PMC_24512546","title":"FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24512546","citation_count":63,"is_preprint":false},{"pmid":"33827814","id":"PMC_33827814","title":"Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer.","date":"2021","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/33827814","citation_count":62,"is_preprint":false},{"pmid":"18688264","id":"PMC_18688264","title":"FOXA1 and IRF-1 intermediary transcriptional regulators of PPARgamma-induced urothelial cytodifferentiation.","date":"2008","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/18688264","citation_count":61,"is_preprint":false},{"pmid":"24948874","id":"PMC_24948874","title":"Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.","date":"2014","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24948874","citation_count":60,"is_preprint":false},{"pmid":"27500525","id":"PMC_27500525","title":"Nucleation of DNA repair factors by FOXA1 links DNA demethylation to transcriptional pioneering.","date":"2016","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27500525","citation_count":56,"is_preprint":false},{"pmid":"38605023","id":"PMC_38605023","title":"FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38605023","citation_count":55,"is_preprint":false},{"pmid":"27034986","id":"PMC_27034986","title":"FOXA1 defines cancer cell specificity.","date":"2016","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/27034986","citation_count":55,"is_preprint":false},{"pmid":"27257062","id":"PMC_27257062","title":"FOXA1 potentiates lineage-specific enhancer activation through modulating TET1 expression and function.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27257062","citation_count":55,"is_preprint":false},{"pmid":"34680352","id":"PMC_34680352","title":"FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34680352","citation_count":54,"is_preprint":false},{"pmid":"17373880","id":"PMC_17373880","title":"FOXA1 as a therapeutic target for breast cancer.","date":"2007","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/17373880","citation_count":53,"is_preprint":false},{"pmid":"19261198","id":"PMC_19261198","title":"FOXA1 in breast cancer.","date":"2009","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19261198","citation_count":52,"is_preprint":false},{"pmid":"21093585","id":"PMC_21093585","title":"Foxa1 and Foxa2 positively and negatively regulate Shh signalling to specify ventral midbrain progenitor identity.","date":"2010","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/21093585","citation_count":52,"is_preprint":false},{"pmid":"38044421","id":"PMC_38044421","title":"hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma.","date":"2023","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38044421","citation_count":49,"is_preprint":false},{"pmid":"25057789","id":"PMC_25057789","title":"Foxa1 and Foxa2 regulate α-cell differentiation, glucagon biosynthesis, and secretion.","date":"2014","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25057789","citation_count":48,"is_preprint":false},{"pmid":"25701738","id":"PMC_25701738","title":"Interactions Between Nuclear Receptor SHP and FOXA1 Maintain Oscillatory Homocysteine Homeostasis in Mice.","date":"2015","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25701738","citation_count":48,"is_preprint":false},{"pmid":"37595040","id":"PMC_37595040","title":"FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37595040","citation_count":47,"is_preprint":false},{"pmid":"22577344","id":"PMC_22577344","title":"Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer.","date":"2012","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/22577344","citation_count":46,"is_preprint":false},{"pmid":"23420418","id":"PMC_23420418","title":"FOXA1 mutations in hormone-dependent cancers.","date":"2013","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23420418","citation_count":45,"is_preprint":false},{"pmid":"38101414","id":"PMC_38101414","title":"FOXA1 forms biomolecular condensates that unpack condensed chromatin to function as a pioneer factor.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/38101414","citation_count":44,"is_preprint":false},{"pmid":"35835117","id":"PMC_35835117","title":"FoxA1 and FoxA2 control growth and cellular identity in NKX2-1-positive lung adenocarcinoma.","date":"2022","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/35835117","citation_count":43,"is_preprint":false},{"pmid":"26336819","id":"PMC_26336819","title":"FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26336819","citation_count":38,"is_preprint":false},{"pmid":"36323682","id":"PMC_36323682","title":"FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36323682","citation_count":37,"is_preprint":false},{"pmid":"37397926","id":"PMC_37397926","title":"Celastrol inhibits gastric cancer cell proliferation, migration, and invasion via the FOXA1/CLDN4 axis.","date":"2023","source":"Toxicology research","url":"https://pubmed.ncbi.nlm.nih.gov/37397926","citation_count":33,"is_preprint":false},{"pmid":"36170835","id":"PMC_36170835","title":"FOXA1 regulates alternative splicing in prostate cancer.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36170835","citation_count":31,"is_preprint":false},{"pmid":"39413792","id":"PMC_39413792","title":"Redirecting the pioneering function of FOXA1 with covalent small molecules.","date":"2024","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/39413792","citation_count":31,"is_preprint":false},{"pmid":"33530829","id":"PMC_33530829","title":"NEDD4 triggers FOXA1 ubiquitination and promotes colon cancer progression under microRNA-340-5p suppression and ATF1 upregulation.","date":"2021","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/33530829","citation_count":31,"is_preprint":false},{"pmid":"25127374","id":"PMC_25127374","title":"Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.","date":"2014","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/25127374","citation_count":31,"is_preprint":false},{"pmid":"34225008","id":"PMC_34225008","title":"The estrogen receptor/GATA3/FOXA1 transcriptional network: lessons learned from breast cancer.","date":"2021","source":"Current opinion in structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/34225008","citation_count":29,"is_preprint":false},{"pmid":"29523221","id":"PMC_29523221","title":"miR-132 Targets FOXA1 and Exerts Tumor-Suppressing Functions in Thyroid Cancer.","date":"2018","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/29523221","citation_count":28,"is_preprint":false},{"pmid":"30624964","id":"PMC_30624964","title":"Dysregulation of miR-431 and target gene FOXA1 in intestinal tissues of infants with necrotizing enterocolitis.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30624964","citation_count":28,"is_preprint":false},{"pmid":"39251788","id":"PMC_39251788","title":"NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.","date":"2024","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39251788","citation_count":27,"is_preprint":false},{"pmid":"31636388","id":"PMC_31636388","title":"Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31636388","citation_count":27,"is_preprint":false},{"pmid":"34518541","id":"PMC_34518541","title":"Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34518541","citation_count":26,"is_preprint":false},{"pmid":"34671430","id":"PMC_34671430","title":"MicroRNA-100 inhibits breast cancer cell proliferation, invasion and migration by targeting FOXA1.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34671430","citation_count":26,"is_preprint":false},{"pmid":"30272002","id":"PMC_30272002","title":"Frequent mutation of the FOXA1 untranslated region in prostate cancer.","date":"2018","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/30272002","citation_count":26,"is_preprint":false},{"pmid":"35550030","id":"PMC_35550030","title":"CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35550030","citation_count":25,"is_preprint":false},{"pmid":"29115441","id":"PMC_29115441","title":"Role of transcription factor FOXA1 in non‑small cell lung cancer.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29115441","citation_count":25,"is_preprint":false},{"pmid":"25264199","id":"PMC_25264199","title":"FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25264199","citation_count":24,"is_preprint":false},{"pmid":"36018068","id":"PMC_36018068","title":"FOXA1 in prostate cancer.","date":"2023","source":"Asian journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/36018068","citation_count":23,"is_preprint":false},{"pmid":"25071007","id":"PMC_25071007","title":"MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25071007","citation_count":23,"is_preprint":false},{"pmid":"24849812","id":"PMC_24849812","title":"Switch in FOXA1 status associates with endometrial cancer progression.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24849812","citation_count":22,"is_preprint":false},{"pmid":"29129808","id":"PMC_29129808","title":"Overexpression of FOXA1 inhibits cell proliferation and EMT of human gastric cancer AGS cells.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/29129808","citation_count":21,"is_preprint":false},{"pmid":"33980863","id":"PMC_33980863","title":"FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036.","date":"2021","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33980863","citation_count":21,"is_preprint":false},{"pmid":"32606743","id":"PMC_32606743","title":"FOXA1 Promotes Cell Proliferation and Suppresses Apoptosis in HCC by Directly Regulating miR-212-3p/FOXA1/AGR2 Signaling Pathway.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32606743","citation_count":21,"is_preprint":false},{"pmid":"27787633","id":"PMC_27787633","title":"Foxa1 gene and protein in developing rat eccrine sweat glands.","date":"2016","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/27787633","citation_count":19,"is_preprint":false},{"pmid":"32235312","id":"PMC_32235312","title":"Frequent FOXA1-Activating Mutations in Extramammary Paget's Disease.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32235312","citation_count":19,"is_preprint":false},{"pmid":"29630912","id":"PMC_29630912","title":"Transcriptome analyses reveal FOXA1 dysregulation in mammary and extramammary Paget's disease.","date":"2018","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29630912","citation_count":19,"is_preprint":false},{"pmid":"34258652","id":"PMC_34258652","title":"FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression.","date":"2021","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34258652","citation_count":18,"is_preprint":false},{"pmid":"29669022","id":"PMC_29669022","title":"DNA-mediated dimerization on a compact sequence signature controls enhancer engagement and regulation by FOXA1.","date":"2018","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/29669022","citation_count":18,"is_preprint":false},{"pmid":"36050295","id":"PMC_36050295","title":"Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36050295","citation_count":17,"is_preprint":false},{"pmid":"38015476","id":"PMC_38015476","title":"Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/38015476","citation_count":17,"is_preprint":false},{"pmid":"35931888","id":"PMC_35931888","title":"FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35931888","citation_count":17,"is_preprint":false},{"pmid":"32831649","id":"PMC_32831649","title":"FOXA1-induced circOSBPL10 potentiates cervical cancer cell proliferation and migration through miR-1179/UBE2Q1 axis.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/32831649","citation_count":17,"is_preprint":false},{"pmid":"34323272","id":"PMC_34323272","title":"The pioneer transcription factors Foxa1 and Foxa2 regulate alternative RNA splicing during thymocyte positive selection.","date":"2021","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34323272","citation_count":17,"is_preprint":false},{"pmid":"26708273","id":"PMC_26708273","title":"FOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations.","date":"2016","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/26708273","citation_count":17,"is_preprint":false},{"pmid":"37549269","id":"PMC_37549269","title":"SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37549269","citation_count":17,"is_preprint":false},{"pmid":"30941644","id":"PMC_30941644","title":"Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer.","date":"2019","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30941644","citation_count":16,"is_preprint":false},{"pmid":"32450521","id":"PMC_32450521","title":"FOXA1-induced LINC01207 facilitates head and neck squamous cell carcinoma via up-regulation of TNRC6B.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32450521","citation_count":16,"is_preprint":false},{"pmid":"31046116","id":"PMC_31046116","title":"The ubiquitinase ZFP91 promotes tumor cell survival and confers chemoresistance through FOXA1 destabilization.","date":"2020","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/31046116","citation_count":16,"is_preprint":false},{"pmid":"34991620","id":"PMC_34991620","title":"FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma.","date":"2022","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34991620","citation_count":16,"is_preprint":false},{"pmid":"29424896","id":"PMC_29424896","title":"Silencing FOXA1 gene regulates liver cancer cell apoptosis and cell proliferation.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29424896","citation_count":15,"is_preprint":false},{"pmid":"37658700","id":"PMC_37658700","title":"FOXA1 prolongs S phase and promotes cancer progression in non-small cell lung cancer through upregulation of CDC5L and activation of the ERK1/2 and JAK2 pathways.","date":"2023","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37658700","citation_count":15,"is_preprint":false},{"pmid":"28938408","id":"PMC_28938408","title":"Pioneer Factors FOXA1 and FOXA2 Assist Selective Glucocorticoid Receptor Signaling in Human Endometrial Cells.","date":"2017","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28938408","citation_count":14,"is_preprint":false},{"pmid":"37817120","id":"PMC_37817120","title":"FOXA1/MND1/TKT axis regulates gastric cancer progression and oxaliplatin sensitivity via PI3K/AKT signaling pathway.","date":"2023","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/37817120","citation_count":14,"is_preprint":false},{"pmid":"30061015","id":"PMC_30061015","title":"Foxa1 and Foxa2 in thymic epithelial cells (TEC) regulate medullary TEC and regulatory T-cell maturation.","date":"2018","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/30061015","citation_count":14,"is_preprint":false},{"pmid":"32685483","id":"PMC_32685483","title":"FOXA1 Expression in Nasopharyngeal Carcinoma: Association with Clinicopathological Characteristics and EMT Markers.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/32685483","citation_count":13,"is_preprint":false},{"pmid":"35203384","id":"PMC_35203384","title":"A Transcriptional Link between HER2, JAM-A and FOXA1 in Breast Cancer.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35203384","citation_count":13,"is_preprint":false},{"pmid":"32655839","id":"PMC_32655839","title":"IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells.","date":"2020","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/32655839","citation_count":13,"is_preprint":false},{"pmid":"28238418","id":"PMC_28238418","title":"FOXA1 is expressed in ovarian mucinous neoplasms.","date":"2017","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28238418","citation_count":13,"is_preprint":false},{"pmid":"31888566","id":"PMC_31888566","title":"Androgen receptor and FOXA1 coexpression define a \"luminal-AR\" subtype of feline mammary carcinomas, spontaneous models of breast cancer.","date":"2019","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31888566","citation_count":13,"is_preprint":false},{"pmid":"38886389","id":"PMC_38886389","title":"TGF-β1 facilitates gallbladder carcinoma metastasis by regulating FOXA1 translation efficiency through m6A modification.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38886389","citation_count":12,"is_preprint":false},{"pmid":"38682180","id":"PMC_38682180","title":"FOXA1/UBE2T Inhibits CD8+T Cell Activity by Inducing Mediates Glycolysis in Lung Adenocarcinoma.","date":"2024","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/38682180","citation_count":12,"is_preprint":false},{"pmid":"31221478","id":"PMC_31221478","title":"SOX9 dependent FOXA1 expression promotes tumorigenesis in lung carcinoma.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31221478","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48986,"output_tokens":10398,"usd":0.151464,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21171,"output_tokens":3953,"usd":0.10234,"stage2_stop_reason":"end_turn"},"total_usd":0.253804,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"FOXA1 acts as a pioneer factor that determines genome-wide ER chromatin binding and gene expression; almost all ER-chromatin interactions depended on FOXA1 presence, and FOXA1 influenced genome-wide chromatin accessibility. CTCF was identified as an upstream negative regulator of FOXA1-chromatin interactions.\",\n      \"method\": \"ChIP-seq, siRNA knockdown, chromatin accessibility assays in breast cancer cells\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq with loss-of-function showing near-complete dependency of ER binding on FOXA1; highly cited, replicated finding\",\n      \"pmids\": [\"21151129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Class-1 FOXA1 wing-2 domain mutations enhance chromatin mobility and binding frequency, strongly transactivating a luminal androgen-receptor program. Class-2 C-terminal truncation mutations increase DNA affinity enabling dominant chromatin binding and promote WNT pathway-driven metastasis through TLE3 inactivation. Class-3 rearrangements reposition a regulatory element (FOXMIND) to drive FOXA1 overexpression.\",\n      \"method\": \"Aggregate cohort genomic analysis, functional cell-based assays, structural classification of mutations\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — large cohort (1,546 cancers) with functional mechanistic follow-up across three structurally distinct mutation classes\",\n      \"pmids\": [\"31243372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Wing-2 FOXA1 mutations confer gain-of-function with exaggerated pro-luminal differentiation; R219 mutations block luminal differentiation and activate a neuroendocrine/mesenchymal program by altering DNA-binding preference from canonical (GTAAAC/T) to a non-canonical motif (GTAAAG/A), as shown by ATAC-seq and reporter assays.\",\n      \"method\": \"Mouse prostate organoid proliferation assays, ATAC-seq, reporter assays, mutagenesis of 14 FOXA1 variants\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (ATAC-seq, organoid assays, reporter with motif mutagenesis) in one rigorous study\",\n      \"pmids\": [\"31243370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LSD1 (KDM1A) associates with FOXA1 and promotes FOXA1 chromatin binding by demethylating FOXA1 at lysine-270, adjacent to the wing-2 region of the forkhead DNA-binding domain. LSD1 inhibition globally disrupts FOXA1 chromatin binding and downstream androgen-receptor binding.\",\n      \"method\": \"Co-IP, ChIP-seq, in vitro demethylation assays, site-directed mutagenesis of K270, in vivo xenograft models\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical demethylation assay with mutagenesis plus genome-wide ChIP-seq and in vivo validation\",\n      \"pmids\": [\"32868907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EZH2 methylates FOXA1 at lysine-295; this methylation is recognized by BUB3, which recruits USP7 deubiquitinase to remove ubiquitination and stabilize FOXA1 protein. This PTM cascade promotes prostate cancer growth and cell cycle gene regulation.\",\n      \"method\": \"In vitro methylation assays, Co-IP, ubiquitination assays, siRNA knockdown, xenograft tumor models\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation assay plus Co-IP/ubiquitination assays identifying writer (EZH2), reader (BUB3), and eraser (USP7) in single study\",\n      \"pmids\": [\"33827814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SETD7 is the methyltransferase responsible for methylating FOXA1 at K270, counteracting LSD1-mediated demethylation; SETD7-mediated K270 methylation disrupts FOXA1 chromatin binding and transcriptional activity, and SETD7 acts as a tumor suppressor in prostate cancer.\",\n      \"method\": \"In vitro methyltransferase assay, ChIP-seq, knockdown/overexpression experiments, prostate cancer cell and in vivo models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methyltransferase assay identifying specific writer enzyme plus genome-wide functional validation\",\n      \"pmids\": [\"37549269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXA1 associates with DNA repair complexes and is required for genomic targeting of DNA polymerase β (POLB). FOXA1-mediated recruitment of POLB drives lineage-specific DNA demethylation at FOXA1-bound regions, and this demethylation is tightly coupled to ER genomic targeting and estrogen responsiveness.\",\n      \"method\": \"Co-IP, genome-wide DNA methylome, POLB ChIP-seq, FOXA1 depletion with rescue, overexpression studies\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with genome-wide methylome and ChIP-seq, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"27500525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXA1 induces TET1 expression by direct binding to TET1 cis-regulatory elements and physically interacts with TET1 protein through its CXXC domain, forming a feed-forward loop that maintains DNA hypomethylation and H3K4 methylation at lineage-specific enhancers to potentiate FOXA1 chromatin recruitment.\",\n      \"method\": \"ChIP-seq, Co-IP, TET1 depletion, genome-wide methylation analysis, reporter assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus genome-wide ChIP-seq and methylation data, multiple orthogonal methods\",\n      \"pmids\": [\"27257062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FOXA1 is not required for AR direct chromatin binding at high-affinity AREs, but recruits AR to low-affinity half-AREs by opening chromatin around adjacent FKHD sites. Excess FOXA1 creates chromatin reservoirs retaining AR via half-AREs; FOXA1 downregulation releases AR to broadly bind AREs genome-wide even without androgen, revealing a dual pioneer and AR-inhibitory role.\",\n      \"method\": \"ChIP-seq, siRNA knockdown/overexpression, FOXA1 titration experiments in prostate cancer cells\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq with mechanistic titration experiments showing cooperativity and equilibrium\",\n      \"pmids\": [\"24875621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FoxA1 depletion causes significant redistribution of both androgen receptor (AR) and glucocorticoid receptor (GR) cistromes in a cell-type- and receptor-specific manner, demonstrating a function for FoxA1 beyond pioneer activity in specifying cell-type specificity of steroid receptor binding.\",\n      \"method\": \"ChIP-seq after FOXA1 depletion, gene expression profiling in LNCaP-1F5 and VCaP cells\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-seq with loss-of-function across two cell lines and two receptors\",\n      \"pmids\": [\"23269278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FOXA1 is essential for ERα expression in mammary gland; Foxa1-null mice show loss of ERα expression and failure of hormone-induced ductal morphogenesis with absent terminal end buds, while GATA3 expression is maintained. In breast cancer cell lines, FOXA1 directly regulates ERα expression.\",\n      \"method\": \"Foxa1 knockout mouse model, mammary gland phenotyping, breast cancer cell line knockdown, RT-PCR and immunostaining\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout mouse with defined phenotype, replicated in cell lines\",\n      \"pmids\": [\"20501593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Foxa1 and Foxa2 together are required for lung branching morphogenesis; double-knockout inhibits cell proliferation, epithelial differentiation, and branching with loss of Shh signaling. Foxa1 and Foxa2 regulate Shh and Shh-dependent genes in respiratory epithelial cells.\",\n      \"method\": \"Conditional double-knockout mouse models (Foxa2Δ/Δ;Foxa1-/-), gene expression analysis, histology\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic double-knockout with defined pathway (Shh) and phenotypic rescue analysis\",\n      \"pmids\": [\"15668254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In NEPC, FOXA1 is reprogrammed from androgen-receptor-associated to neuroendocrine-specific regulatory elements. NEPC requires FOXA1 for proliferation and NE lineage gene expression. Ectopic expression of ASCL1 and NKX2-1 in prostate adenocarcinoma cells is sufficient to reprogram FOXA1 binding to NE regulatory elements and induce enhancer activity.\",\n      \"method\": \"ChIP-seq (histone modifications), FOXA1 knockdown, ectopic TF expression, patient-derived xenografts\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq in PDX models plus functional knockdown and ectopic TF reprogramming with multiple orthogonal methods\",\n      \"pmids\": [\"33785741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FOXA1 directly occupies an upstream enhancer of TGFB3 to inhibit its transcription; FOXA1 loss upregulates TGFβ3, which activates TGF-β signaling, EMT, and cell motility. Pharmacological TGF-β receptor I inhibition blocks FOXA1 loss-induced invasion.\",\n      \"method\": \"ChIP assay, siRNA knockdown, SMAD2 phosphorylation measurement, tissue microarray, xenograft invasion assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP confirming direct enhancer occupancy plus in vivo xenograft rescue with pharmacological inhibitor\",\n      \"pmids\": [\"30511964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXA1 directly binds the promoter of IL-8 to inhibit its expression; FOXA1 loss induces IL-8, which activates MAPK/ERK pathway (ERK phosphorylation) and ENO2 expression, driving neuroendocrine differentiation. IL-8 knockdown or ERK inhibition abolishes FOXA1 loss-induced NE differentiation.\",\n      \"method\": \"ChIP assay, siRNA knockdown, ERK phosphorylation assay, IL-8 blockade, xenograft models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP establishing direct promoter binding plus pathway validation by multiple perturbations\",\n      \"pmids\": [\"28319070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOXA1 directly binds an intragenic enhancer of HIF1A to inhibit its expression; FOXA1 downregulation induces hypoxia transcriptional programs via HIF1A, which upregulates CCL2 to promote immunosuppressive macrophage infiltration and cancer cell invasion.\",\n      \"method\": \"ChIP assay, siRNA knockdown, HIF1A pharmacological inhibition, macrophage infiltration assays, xenograft invasion studies\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct enhancer binding plus functional cascade validation with pharmacological inhibitors\",\n      \"pmids\": [\"35931888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FOXA1 binds the STAT2 DNA-binding domain and suppresses STAT2 DNA-binding activity and IFN signaling gene expression, suppressing cancer immune response independently of FOXA1 transactivation activity and independently of FOXA1 cancer mutations.\",\n      \"method\": \"Co-IP, ChIP, siRNA knockdown, IFN signaling gene expression assays in prostate and breast cancer cells and mouse models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishing direct STAT2 interaction plus functional gene expression and in vivo validation\",\n      \"pmids\": [\"34101624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FOXA1 forms submicron condensates through N- and C-terminal intrinsically disordered regions (IDRs); these IDRs enable FOXA1 to dissolve condensed chromatin. DNA-binding capacity contributes to both condensate formation and condensed-chromatin dissolution. IDR-mediated condensate formation governs FOXA1 binding to condensed chromatin to regulate proliferation and migration.\",\n      \"method\": \"Live-cell imaging, FRAP, condensate dissolution assays, genome-wide ATAC-seq, IDR deletion mutagenesis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution-like condensate assays with mutagenesis of IDRs and genome-wide functional validation\",\n      \"pmids\": [\"38101414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Covalent small molecules react with FOXA1 at C258 within the forkhead DNA-binding domain in a DNA-dependent manner, redistributing FOXA1 genome-wide binding and altering chromatin accessibility. Motif analysis indicates ligands relax canonical DNA-binding preference by strengthening interactions with suboptimal sequences near C258.\",\n      \"method\": \"Chemical proteomics, ChIP-seq, ATAC-seq, covalent ligand competition assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — covalent site-specific modification with structural mechanism plus genome-wide ChIP-seq and ATAC-seq validation\",\n      \"pmids\": [\"39413792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Both Foxa1 and Foxa2 physically interact with the DNA-binding domain of AR via GST pull-down; this interaction enables Foxa proteins to be recruited to AR binding sites without a Foxa binding site, and AR can be recruited to Foxa binding sites without an AR binding site. Foxa1 regulates prostate-specific genes (PSA, probasin) while Foxa2 regulates epididymis-specific genes (mE-RABP).\",\n      \"method\": \"GST pull-down, gel-shift (EMSA), ChIP, transient transfection reporter assays\",\n      \"journal\": \"Annals of the New York Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — GST pull-down plus EMSA and ChIP, single lab\",\n      \"pmids\": [\"16467259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"FOXA1 binds a specific site in the p27(Kip1) promoter (within the BRCA1-responsive element) to activate p27 transcription. BRCA1 co-expression synergistically activates the p27 promoter and increases FOXA1 protein half-life. Mutation of the FOXA1 binding site abrogates both FOXA1 and BRCA1-mediated activation.\",\n      \"method\": \"EMSA with supershift, transient transfection reporter assays, mutagenesis, half-life analysis, siRNA knockdown of BRCA1\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA with supershift confirming direct DNA binding plus mutagenesis of binding site, single lab\",\n      \"pmids\": [\"16331276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FOXA1 SUMOylation occurs at K6, K389, and K267 (proximal to the DNA-binding domain). Mutation of SUMO sites slows FOXA1 nuclear mobility (FRAP) and further retards AR mobility, enhances FOXA1 chromatin occupancy at the PSA locus, increases FOXA1 transcriptional activity with AR, and alters LNCaP cell proliferation.\",\n      \"method\": \"SUMOylation assays in COS-1 cells, FRAP in HEK293 cells, ChIP, gene expression assays in LNCaP cells\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct SUMOylation assay with site mutagenesis plus FRAP and ChIP, single lab\",\n      \"pmids\": [\"25127374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A compact palindromic DNA element (DIV) induces FOXA1 homodimerization with strongly positive cooperativity, strictly constrained by precise half-site spacing. FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted, and DIV sites show increased accessibility in response to PI3K inhibition.\",\n      \"method\": \"ChIP-seq reanalysis, EMSA cooperativity assays, reporter gene assays, structural modeling\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA demonstrating cooperativity with spacing mutagenesis plus reporter assays and ChIP-seq, single lab\",\n      \"pmids\": [\"29669022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Wing-2 FOXA1 mutations in breast cancer display increased chromatin binding at ER loci upon estrogen stimulation and enhanced ER-mediated transcription without changes in chromatin accessibility. The breast cancer-specific SY242CS mutation opens distinct chromatin regions and activates an alternative cistrome through a conformational change enabling stable binding to a non-canonical DNA motif.\",\n      \"method\": \"ChIP-seq, ATAC-seq, structural modeling, breast cancer patient cohort analysis\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq and ATAC-seq distinguishing mechanistic effects of two mutation classes in breast cancer models\",\n      \"pmids\": [\"32888433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FOXA1 directly inhibits EZH2 histone methyltransferase activity through its C-terminal histone-binding motif, opposing EZH2-mediated CDKN2A repression. Loss of FOXA1 is required, in addition to EZH2 overexpression, to bypass RAS-induced senescence via CDKN2A silencing.\",\n      \"method\": \"In vitro HMTase assay, epistasis experiments (siRNA double knockdown), oncogenic transformation assays in prostate and breast cancer cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro HMTase inhibition assay plus epistasis, single lab, limited mechanistic detail in abstract\",\n      \"pmids\": [\"25264199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Foxa1 and Foxa2 are essential for differentiation of intestinal goblet cells (via Muc2 regulation) and enteroendocrine L- and D-cells (glucagon-like peptide, somatostatin, peptide YY); double intestinal-specific knockout reduces expression of Islet-1 and Pax6, placing Foxa1/2 upstream of a broader enteroendocrine transcription factor network.\",\n      \"method\": \"Villin-Cre conditional double-knockout mice, immunohistochemistry, RT-PCR, mRNA quantification\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean tissue-specific double-knockout with defined cellular phenotypes and gene expression targets\",\n      \"pmids\": [\"19737569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Foxa1 and Foxa2 together control expression of ChREBP (Mlxipl) directly in beta cells; combined inactivation causes impaired glucose-stimulated insulin secretion and calcium oscillations more severe than Foxa2 alone, and elevates neural differentiation genes, demonstrating redundant and distinct roles in maintaining beta-cell metabolic and secretory identity.\",\n      \"method\": \"Inducible conditional double-knockout mice, glucose tolerance tests, calcium imaging, RNA expression profiling\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible KO with direct functional readouts (insulin secretion, calcium oscillations) and ChREBP target gene analysis\",\n      \"pmids\": [\"20534694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Foxa2 directly binds Gli2 genomic regulatory regions (confirmed by ChIP) and, together with Foxa1, attenuates Shh signaling by inhibiting Gli2 transcription in ventral midbrain progenitors. Loss/gain-of-function studies show Foxa1 and Foxa2 positively regulate Shh expression while also negatively regulating its downstream transducer Gli2.\",\n      \"method\": \"ChIP, conditional Wnt1-Cre;Foxa2flox/flox knockout, gain-of-function in mice\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct Gli2 binding plus genetic loss/gain-of-function, single lab\",\n      \"pmids\": [\"21093585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NEDD4 physically interacts with FOXA1 (Co-IP) and triggers its ubiquitination and proteasomal degradation. FOXA1 transcriptionally activates miR-340-5p, which binds ATF1 mRNA. NEDD4-mediated FOXA1 destabilization thus suppresses miR-340-5p and elevates ATF1 to promote colon cancer progression.\",\n      \"method\": \"Co-IP, ubiquitination assay, ChIP, luciferase reporter assay, siRNA experiments in colon cancer cells\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination assay identifying E3 ligase-substrate relationship, single lab\",\n      \"pmids\": [\"33530829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZFP91 ubiquitinates FOXA1 and promotes its degradation; ZFP91 knockdown reduces FOXA1 polyubiquitination, increases FOXA1 protein stability, and sensitizes gastric cancer cells to chemotherapy.\",\n      \"method\": \"Co-IP, ubiquitination assay, ZFP91 siRNA knockdown, protein stability measurement\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay identifying E3 ligase plus functional consequences, single lab\",\n      \"pmids\": [\"31046116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Nuclear receptor SHP inhibits FOXA1-mediated transcriptional activation of Bhmt (betaine-homocysteine methyltransferase) and cystathionine γ-lyase, controlling oscillatory homocysteine metabolism in mice.\",\n      \"method\": \"ChIP, RNA-seq, metabolomics in SHP-null mice, dietary manipulation experiments\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP in vivo plus SHP-null mouse phenotype and metabolomics, single lab\",\n      \"pmids\": [\"25701738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FOXA1 interacts with AR (Co-IP) in endometrial cancer cells and both bind directly to the MYC promoter and enhancer (ChIP). FOXA1 promotes AR-mediated transcription of XBP1, MYC, ZBTB16, and UHRF1, activating Notch1/Hes1 expression in an AR-dependent manner to promote cancer cell proliferation.\",\n      \"method\": \"Co-IP, ChIP-PCR, siRNA/shRNA knockdown, transfection reporter assays, xenograft tumor formation\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and ChIP-PCR establishing direct protein interaction and DNA binding, single lab\",\n      \"pmids\": [\"24512546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Twist1 represses FOXA1 expression by binding the FOXA1 proximal promoter and recruiting the NuRD transcriptional repressor complex to de-acetylate H3K9 and inhibit RNA polymerase II recruitment, and by blocking AP-1 recruitment. Restored FOXA1 expression in Twist1-expressing cells reduces integrin α5, integrin β1 and MMP9 and inhibits invasion/metastasis.\",\n      \"method\": \"ChIP, promoter reporter assays, Co-IP (NuRD recruitment), siRNA/overexpression, xenograft metastasis models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct promoter binding and NuRD complex recruitment plus functional invasion assays, single lab\",\n      \"pmids\": [\"27524420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PPARγ activation induces FOXA1 expression as an intermediary transcription factor; FOXA1 (and IRF-1) bind UPK1a, UPK2, and UPK3a promoters (confirmed by EMSA) and their siRNA knockdown abrogates PPARγ-induced uroplakin expression, placing FOXA1 downstream of PPARγ in a urothelial differentiation program.\",\n      \"method\": \"Microarray, EMSA, siRNA knockdown, gene expression analysis in primary normal human urothelial cells\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA confirming direct DNA binding plus siRNA epistasis showing pathway dependency, single lab\",\n      \"pmids\": [\"18688264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOXA1 directly binds regulatory regions of splicing-related genes including HNRNPK and SRSF1, controlling their expression and thereby orchestrating alternative splicing dysregulation across prostate cancer transcriptomes through an 'exon definition' mechanism that reduces NMD-targeted isoforms.\",\n      \"method\": \"ChIP-seq, transcriptome analysis of 500 prostate cancer samples, siRNA knockdown, functional cell proliferation assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq plus large-scale transcriptome analysis with functional validation, single lab\",\n      \"pmids\": [\"36170835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"O-GlcNAcylation of FOXA1 at Thr432, Ser441, and Ser443 regulates FOXA1 protein stability and chromatin assembly. O-GlcNAcylation triggers recruitment of the transcriptional repressor MeCP2 to FOXA1, switching FOXA1 chromatin-binding sites to adhesion-related gene loci (EPB41L3, COL9A2) to promote breast cancer metastasis.\",\n      \"method\": \"Site-specific mutagenesis, Co-IP, ChIP-seq, ATAC-seq, in vitro and in vivo metastasis assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-specific PTM mutagenesis with Co-IP identifying reader (MeCP2) plus genome-wide ChIP-seq and in vivo validation\",\n      \"pmids\": [\"37595040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CREB5 physically interacts with FOXA1 and AR at transcription regulatory elements active in mCRPC, reprogramming FOXA1 nuclear protein-protein interaction network in response to enzalutamide. CREB5/FOXA1 co-interacting factors TBX3 and NFIC regulate cell viability and ART resistance.\",\n      \"method\": \"ChIP-seq, rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME), Co-IP, patient transcriptome analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIME/Co-IP identifying nuclear interaction partners with ChIP-seq validation, single lab\",\n      \"pmids\": [\"35550030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NSD2 associates with FOXA1 at tumor-specific AR enhancers containing the chimeric FOXA1:AR half-motif; NSD2 inactivation disrupts >65% of the AR cistrome and impairs AR transactivation. NSD2 H3K36 dimethyltransferase activity is required for these AR/FOXA1-dependent enhancer circuitries.\",\n      \"method\": \"ChIP-seq, NSD2 inactivation, FOXA1 ChIP, motif analysis, PROTAC degrader studies in prostate cancer models\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq with genetic inactivation and pharmacological degradation, identifying NSD2 as essential co-factor at FOXA1:AR enhancers\",\n      \"pmids\": [\"39251788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FOXA1-mediated repression of GR (NR3C1) occurs via the corepressor TLE3; FOXA1 silencing potentiates GR chromatin binding and transcriptional activity rather than restricting it. Pre-accessible chromatin sites with FOXA1 occupancy are the exclusive sites of AR-to-GR replacement under enzalutamide treatment.\",\n      \"method\": \"Genome-wide ChIP-seq, ATAC-seq, FOXA1 siRNA silencing, TLE3 Co-IP/ChIP in prostate cancer cells\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-seq and ATAC-seq with FOXA1 silencing revealing mechanistic TLE3-corepressor link, single lab\",\n      \"pmids\": [\"38015476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXA1 transcriptionally activates the PLOD2 promoter by directly binding it; this occurs downstream of a PI3K/AKT signaling axis (EGFR-PI3K/AKT-FOXA1-PLOD2), and elevated PLOD2 promotes NSCLC metastasis by enhancing migration and collagen reorganization.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, siRNA knockdown, orthotopic implantation metastasis model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay confirming direct promoter binding, with in vivo metastasis validation, single lab\",\n      \"pmids\": [\"29072684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FOXA1 depletion in CRPC cells abrogates oncogenic potential of constitutively active AR variants (AR-Vs); ~41% of the AR-V transcriptome requires FOXA1, and FOXA1 depletion attenuates AR-V chromatin binding at co-regulated genes. AR-V protein levels paradoxically increase upon FOXA1 loss due to loss of negative feedback on the AR gene.\",\n      \"method\": \"FOXA1 siRNA/shRNA knockdown, gene expression profiling, AR-V ChIP, proliferation assays in CWR22Rv1 cells\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus genome-wide expression profiling with loss-of-function, single lab\",\n      \"pmids\": [\"26336819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Foxa1 and Foxa2 directly bind and activate promoter regions of Nkx2.2, Kir6.2, Sur1, Gipr, Isl1, and Pou3f4 genes in alpha cells. Foxa1 specifically regulates glucagon gene expression through the G2 element, while combined Foxa1/Foxa2 depletion is required to affect glucagon secretion.\",\n      \"method\": \"siRNA knockdown of Foxa1 and Foxa2 in primary rat alpha cells, ChIP, qPCR, glucagon secretion assays\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP in primary cells confirming direct promoter binding plus functional secretion assays, single lab\",\n      \"pmids\": [\"25057789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Pioneer factors FOXA1 and FOXA2 are required for glucocorticoid receptor (GR) recruitment to the LEFTY1 promoter in endometrial cells; E2 antagonizes glucocorticoid-mediated LEFTY1 induction by reducing FOXA1, FOXA2, and GR recruitment. Multiple additional GR-dependent genes require FOXA1/2 for induction.\",\n      \"method\": \"ChIP showing GR and FOXA1/2 co-recruitment, siRNA knockdown of FOXA1/2, gene expression profiling in immortalized and primary human endometrial cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating co-recruitment with functional knockdown, single lab\",\n      \"pmids\": [\"28938408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FOXA1 directly binds the MND1 promoter to inhibit its transcription (ChIP and luciferase assay); MND1 interacts with TKT (Co-IP and mass spectrometry) and activates the PI3K/AKT signaling axis to promote gastric cancer progression and oxaliplatin resistance.\",\n      \"method\": \"Luciferase reporter assay, ChIP, Co-IP, mass spectrometry, siRNA knockdown, in vitro and in vivo assays\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus Co-IP/MS identifying downstream partner, single lab\",\n      \"pmids\": [\"37817120\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FOXA1 is a pioneer transcription factor that binds condensed chromatin through its forkhead DNA-binding domain—aided by intrinsically disordered regions that form condensates to dissolve compact chromatin—and opens local chromatin to license binding of steroid hormone receptors (ERα, AR, GR); its chromatin occupancy and activity are post-translationally regulated by LSD1-mediated demethylation at K270 (stabilizing binding), SETD7-mediated methylation at K270 (disrupting binding), EZH2-mediated methylation at K295 recognized by BUB3/USP7 (stabilizing protein), SUMOylation at K6/K389/K267 (modulating nuclear mobility), O-GlcNAcylation at Thr432/Ser441/Ser443 (altering interactome and cistrome), and ubiquitination by NEDD4/ZFP91 (promoting degradation); FOXA1 also directly represses target gene transcription (TGFB3, IL-8, HIF1A, MND1) and suppresses IFN signaling by binding the STAT2 DNA-binding domain, while associating with DNA repair complexes to drive POLB-dependent DNA demethylation and cooperating with TET1 via a feed-forward loop to maintain lineage-specific enhancer hypomethylation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FOXA1 is a pioneer transcription factor that opens compacted chromatin to license recruitment of steroid hormone receptors and to specify lineage-specific gene-expression programs across mammary, prostate, lung, intestinal, pancreatic, and urothelial tissues [#0, #11, #25, #26]. It establishes the genome-wide chromatin-binding landscape of estrogen receptor (almost all ERα–chromatin interactions depend on FOXA1) and reciprocally controls androgen-receptor and glucocorticoid-receptor cistromes in a cell-type- and receptor-specific manner; FOXA1 and AR can physically interact through the AR DNA-binding domain, enabling mutual recruitment to sites lacking a cognate motif [#0, #9, #19]. Its pioneering capacity rests on a forkhead DNA-binding domain together with N- and C-terminal intrinsically disordered regions that drive condensate formation and dissolution of condensed chromatin [#17]. Beyond licensing receptors, FOXA1 displays a dual inhibitory role—buffering AR and GR through chromatin reservoirs and the corepressor TLE3—so that FOXA1 loss can release receptors to bind chromatin more broadly [#8, #38]. FOXA1 also directly represses transcription of genes including TGFB3, IL-8, HIF1A, and MND1, restraining EMT, neuroendocrine differentiation, hypoxia programs, and invasion when present, and it suppresses interferon signaling by binding and inhibiting the STAT2 DNA-binding domain independently of its own transactivation [#13, #14, #15, #16]. FOXA1 chromatin occupancy and stability are tuned by an extensive post-translational code: LSD1 demethylates K270 to stabilize binding while SETD7 methylates the same residue to disrupt it, EZH2-mediated K295 methylation is read by BUB3 to recruit USP7 and stabilize the protein, SUMOylation and O-GlcNAcylation reshape mobility and cistrome, and the E3 ligases NEDD4 and ZFP91 target it for degradation [#3, #5, #4, #21, #35, #28, #29]. FOXA1 further couples transcription to epigenome remodeling by recruiting DNA polymerase β to drive lineage-specific DNA demethylation and by forming a feed-forward loop with TET1 to maintain enhancer hypomethylation [#6, #7]. Cancer-associated mutations partition into mechanistically distinct classes that enhance chromatin mobility, increase DNA affinity, or relax DNA-motif preference to activate alternative cistromes and drive luminal, neuroendocrine, metastatic, or WNT-driven programs [#1, #2, #23].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established that FOXA1 acts in tissue morphogenesis and engages steroid receptors directly, framing it as both a developmental regulator and a receptor partner.\",\n      \"evidence\": \"Foxa1/Foxa2 double-knockout mice for lung branching plus GST pull-down with the AR DNA-binding domain\",\n      \"pmids\": [\"15668254\", \"16467259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of chromatin opening not yet addressed\", \"AR interaction shown only by pull-down/EMSA in a single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined FOXA1 as the pioneer factor that dictates genome-wide ER binding and is essential for ERα expression and hormone-driven mammary morphogenesis, anchoring its role in hormone-responsive epithelia.\",\n      \"evidence\": \"ChIP-seq with siRNA knockdown in breast cancer cells and Foxa1-null mouse mammary phenotyping\",\n      \"pmids\": [\"21151129\", \"20501593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biophysical basis of chromatin opening unresolved\", \"Did not address regulation of FOXA1 itself\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed FOXA1 as a quantitative, dual regulator of AR—opening chromatin to recruit AR to low-affinity sites while also sequestering AR in reservoirs—rather than a simple positive pioneer.\",\n      \"evidence\": \"ChIP-seq with FOXA1 titration, knockdown, and overexpression in prostate cancer cells\",\n      \"pmids\": [\"24875621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the corepressor mediating sequestration\", \"Equilibrium parameters not measured biochemically\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected FOXA1 transcriptional pioneering to active DNA-demethylation, showing it shapes the lineage epigenome through POLB recruitment and a TET1 feed-forward loop.\",\n      \"evidence\": \"Reciprocal Co-IP, genome-wide methylome, POLB ChIP-seq, and TET1 depletion experiments\",\n      \"pmids\": [\"27500525\", \"27257062\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct enzymatic coupling of FOXA1 to demethylation machinery not reconstituted\", \"Generality across non-breast lineages untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Resolved the functional consequences of cancer mutations into structurally distinct classes that alter chromatin mobility, DNA affinity, or motif preference, explaining how FOXA1 alterations drive divergent oncogenic programs.\",\n      \"evidence\": \"Large cohort genomics with functional cell assays, organoid proliferation, ATAC-seq, and motif mutagenesis\",\n      \"pmids\": [\"31243372\", \"31243370\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural details of altered DNA-binding inferred, not crystallographically resolved\", \"In vivo tumor initiation by each class incompletely tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified K270 methylation status as a switch controlling FOXA1 chromatin binding, with LSD1 demethylation stabilizing occupancy.\",\n      \"evidence\": \"Co-IP, in vitro demethylation assays, K270 mutagenesis, ChIP-seq, and xenografts\",\n      \"pmids\": [\"32868907\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Opposing writer not yet identified at this stage\", \"Stoichiometry of modification in vivo unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Expanded the PTM code by defining EZH2→BUB3→USP7 K295 methyl-stabilization and a STAT2-binding immune-suppressive activity, plus NEDD4 ubiquitination, distinguishing FOXA1 stability and non-genomic functions.\",\n      \"evidence\": \"In vitro methylation/ubiquitination assays, Co-IP for STAT2 and NEDD4, ChIP, and in vivo models\",\n      \"pmids\": [\"33827814\", \"34101624\", \"33530829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between competing PTMs not integrated\", \"STAT2 suppression structural interface not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined SETD7 as the K270 methyltransferase opposing LSD1 and established O-GlcNAcylation as a cistrome-switching modification recruiting MeCP2, completing a writer/eraser logic for FOXA1 regulation.\",\n      \"evidence\": \"In vitro methyltransferase assays, site-specific PTM mutagenesis, Co-IP, ChIP-seq, ATAC-seq, and metastasis models\",\n      \"pmids\": [\"37549269\", \"37595040\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Combinatorial effect of K270 methylation and O-GlcNAcylation untested\", \"Upstream signals controlling these enzymes in vivo unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided a biophysical basis for pioneering by showing FOXA1 IDRs form condensates that dissolve condensed chromatin.\",\n      \"evidence\": \"Live-cell imaging, FRAP, condensate dissolution assays, ATAC-seq, and IDR deletion mutagenesis\",\n      \"pmids\": [\"38101414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Composition of FOXA1 condensates in vivo not defined\", \"Link between condensates and specific PTMs unexplored\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated druggability and cofactor dependence of the FOXA1 cistrome through covalent C258 ligands that relax DNA preference and NSD2-dependent H3K36 methylation that sustains FOXA1:AR enhancers.\",\n      \"evidence\": \"Chemical proteomics, ChIP-seq, ATAC-seq, NSD2 genetic inactivation, and PROTAC degraders in prostate cancer models\",\n      \"pmids\": [\"39413792\", \"39251788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic window of covalent ligands not established\", \"How NSD2 is recruited specifically to FOXA1:AR sites unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the full set of competing PTMs, condensate dynamics, and cofactor circuits are integrated to determine FOXA1's tissue- and context-specific cistrome remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified quantitative model linking PTM state to chromatin output\", \"Structural mechanism of mutant motif relaxation not solved\", \"In vivo interplay of activator vs repressor roles per tissue undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 13, 14, 16]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 18, 22, 23]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 16, 38]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [17, 21]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [0, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 13, 14]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 8, 9]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [10, 11, 25, 26]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [6, 7, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 2, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"AR\", \"ESR1\", \"LSD1\", \"EZH2\", \"TET1\", \"STAT2\", \"TLE3\", \"NSD2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}